Krystal Biotech (KRYS)
NASDAQ:KRYS

Krystal Biotech (KRYS) Stock Forecast & Price Target

261 Followers
See the Price Targets and Ratings of:

KRYS Analyst Ratings

Moderate Buy
3Ratings
2 Buy
1 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Krystal
Biotech
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

KRYS Stock 12 Months Forecast

Average Price Target

$110.33
▲(39.39% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Krystal Biotech in the last 3 months. The average price target is $110.33 with a high forecast of $133.00 and a low forecast of $79.00. The average price target represents a 39.39% change from the last price of $79.15.
Highest Price Target$133.00Average Price Target$110.33Lowest Price Target$79.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
William Blair
Buy
Reiterated
Analysts Offer Insights on Healthcare Companies: Krystal Biotech (NASDAQ: KRYS) and Cogent Biosciences (NASDAQ: COGT)
Guggenheim
$101.00
Buy
27.61%
Upside
Reiterated
Krystal Biotech price target lowered to $101 from $114 at GuggenheimKrystal Biotech price target lowered to $101 from $114 at Guggenheim
Cowen & Co.
$111.00
Buy
40.24%
Upside
Reiterated
Cowen reiterates Outperform Rating on Krystal Biotech (KRYS), "Remain Encouraged by New Durability Analyses"Cowen analyst Ritu Baral reiterated an Outperform rating and $111.00 price target on Krystal Biotech (NASDAQ: KRYS), following the companys report of new data from Vyjuveks Phase 3 study.
Canaccord Genuity
$114.00
Buy
44.03%
Upside
Reiterated
Krystal Biotech (KRYS) PT Lowered to $114 at GuggenheimGuggenheim analyst Whitney Ijem lowered the price target on Krystal Biotech (NASDAQ: KRYS) to $114.00 (from $133.00) while maintaining a Buy rating.
Bank of America Securities
$110.00
Buy
38.98%
Upside
Initiated
Krystal Biotech initiated with a Buy at BofAKrystal Biotech initiated with a Buy at BofA
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

KRYS Financial Forecast

KRYS Earnings Forecast
Next quarter’s earnings estimate for KRYS is -$1.01 with a range of -$1.50 to $1.01. The previous quarter’s EPS was -$1.17. KRYS beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.52% of the time in the same period. In the last calendar year KRYS has Underperformed its overall industry.
Next quarter’s earnings estimate for KRYS is -$1.01 with a range of -$1.50 to $1.01. The previous quarter’s EPS was -$1.17. KRYS beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.52% of the time in the same period. In the last calendar year KRYS has Underperformed its overall industry.
No data currently available
KRYS Sales Forecast
Next quarter’s sales forecast for KRYS is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. KRYS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 42.85% of the time in the same period. In the last calendar year KRYS has Underperformed its overall industry.
Next quarter’s sales forecast for KRYS is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. KRYS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 42.85% of the time in the same period. In the last calendar year KRYS has Underperformed its overall industry.
KRYS Analyst Recommendation Trends
In the current month, KRYS has received 2 Buy ratings 1 Hold ratings, and 0 Sell ratings. The KRYS average analyst price target in the past 3 months is $110.33
In the current month, KRYS has received 2 Buy ratings 1 Hold ratings, and 0 Sell ratings. The KRYS average analyst price target in the past 3 months is $110.33

KRYS Stock Forecast FAQ

What is KRYS’s average 12-month price target, according to analysts?
Based on analyst ratings, Krystal Biotech’s 12-month average price target is $110.33.
    What is KRYS’s upside potential, based on the analysts’ average price target?
    Krystal Biotech has 39.39% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is KRYS a Buy, Sell or Hold?
          Krystal Biotech has a conensus rating of Moderate Buy which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Krystal Biotech’s price target?
            The average price target for Krystal Biotech is $110.33. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $133.00 ,the lowest forecast is $79.00. The average price target represents 39.39% Increase from the current price of $79.15.
              What do analysts say about Krystal Biotech?
              Krystal Biotech’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis